ERBB2 and breast carcinoma: With the widely recommended use of anti-HER2 target drugs for treatment of HER2-positive breast cancer patients in metastatic disease due to the benefits in overall survival and progression-free survival, it is important to explore the molecular mechanisms behind the good results of this therapy and monitor them.